title: Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose?
abstract: In view of the central pathogenic importance of leukocyte extravasation in inflammatory skin diseases, therapeutic interference with this - surprisingly complex - process is clearly a promising new approach for treating these dermatoses. Despite some disappointments during the clinical use of these agents and despite their crippling price tag, the recent incorporation of biologicals that target defined molecular controls of leukocyte extravasation into dermatological and rheumatological practise, consequently, has greatly enriched our therapeutic options for battling major, chronic, inflammatory dermatoses such as psoriasis. However, the - as yet unresolved and still rather controversially discussed - critical question is: Which of the multiple steps that control leukocyte extravasation in the human system really offer the most promising, most pragmatic, and safest molecular targets for therapeutic intervention for which disease entity? The current debate intends to stimulate public and rational debate of this crucial issue, beyond the evident commercial interests that are touched by whatever stand one takes.
authors.forename: W-H
authors.initials: WH
authors.lastname: Boehncke
authors.forename: M P
authors.initials: MP
authors.lastname: Schön
authors.forename: G
authors.initials: G
authors.lastname: Girolomoni
authors.forename: G
authors.initials: G
authors.lastname: Giromolomi
authors.forename: C
authors.initials: C
authors.lastname: Griffiths
authors.forename: J D
authors.initials: JD
authors.lastname: Bos
authors.forename: K
authors.initials: K
authors.lastname: Thestrup-Pedersen
authors.forename: A
authors.initials: A
authors.lastname: Cavani
authors.forename: F
authors.initials: F
authors.lastname: Nestle
authors.forename: B K
authors.initials: BK
authors.lastname: Bonish
authors.forename: J J
authors.initials: JJ
authors.lastname: Campbell
authors.forename: C
authors.initials: C
authors.lastname: Brakebusch
authors.forename: B
authors.initials: B
authors.lastname: Nickoloff
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D002448:Cell Adhesion / Q000187:drug effects / Q000276:immunology; D015815:Cell Adhesion Molecules / Q000187:drug effects / Q000276:immunology; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology; D003872:Dermatitis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D036904:Leukocyte Rolling / Q000187:drug effects / Q000276:immunology; D007962:Leukocytes / Q000187:drug effects* / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D023421:Models, Animal; D018448:Models, Immunological; D012871:Skin Diseases / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; D015815:Cell Adhesion Molecules; D007166:Immunosuppressive Agents